SavedAdd your journal

Journals / art / 2019 / Cilt: 34 - Sayı: 4

Familial Mediterranean Fever and Multiple Sclerosis Successfully Treated With Interferon Beta-1a: A Case Report

Bilgin ÖZTÜRK
Journal
art
Pages
443–446
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Interferon beta can be a treatment of choice in patients with coincident FMF and MS and can be used in colchicine-resistant patients after being studied in systematic clinical studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Multiple sclerosis (MS) is the most common demyelinating disease in Turkey while familial Mediterranean fever (FMF) is the most common periodic fever syndrome worldwide.
📊
Key Findings & Data:In this article, we report a 37-year-old male patient admitted with complaint of difficulty in walking.
💡
Conclusion & Impact:Interferon beta can be a treatment of choice in patients with coincident FMF and MS and can be used in colchicine-resistant patients after being studied in systematic clinical studies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Multiple sclerosis (MS) is the most common demyelinating disease in Turkey while familial Mediterranean fever (FMF) is the most common periodic fever syndrome worldwide. In this article, we report a 37-year-old male patient admitted with complaint of difficulty in walking. He had been taking colchicine at admission for 27 years. Despite this therapy, he had been experiencing twice monthly severe FMF attacks. After systemic and neurological examinations, laboratory tests and cranial and spinal magnetic resonance imaging, he was diagnosed as MS. Interferon (IFN) beta-1a was initiated three times/weekly subcutaneously for MS treatment. He stopped colchicine treatment after five months of IFN treatment because he did not suffer from any FMF attacks. He is still attack free for both diseases for a follow-up duration of 12 months. IFN beta is one of the most preferred agents for MS treatment but not one of the agents used for the treatment of FMF. Interferon beta can be a treatment of choice in patients with coincident FMF and MS and can be used in colchicine-resistant patients after being studied in systematic clinical studies.

🔖

Cite This Article

ÖZTÜRK, B. (2019). Familial Mediterranean Fever and Multiple Sclerosis Successfully Treated With Interferon Beta-1a: A Case Report. art, Cilt: 34 - Sayı: 4, 443–446. https://ajindex.com/articles/148271

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Medlej-Hashim M, Nehme N, Chouery E, Jalkh N, Megarbane A. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. BMC Med Genet 2010;11:87
  2. Aksu K, Keser G. Coexistence of vasculitides with familial Mediterranean fever. Rheumatol Int 2011;31:1263-74
  3. Akman-Demir G, Gul A, Gurol E, Ozdogan H, Bahar S, Oge AE, et al. Inflammatory/demyelinating central nervous system involvement in familial Mediterranean fever (FMF): coincidence or association? J Neurol 2006;253:928-34
  4. Schwabe AD, Monroe JB. Meningitis in familial Mediterranean fever. Am J Med 1988;85:715-7
  5. Topçuo¤lu MA, Karabudak R. Familial Mediterranean fever and multiple sclerosis. J Neurol 1997;244:510-4
  6. Ugurlu S, Bolayir E, Candan F, Gumus C. Familial mediterranean fever and multiple sclerosis--a case report. Acta Reumatol Port 2009;34:117-9
  7. Sayin R, Alpayci M, Soyoral YU. A case with multiple sclerosis and familial Mediterranean fever. Genet Couns 2011;22:309-12
  8. Karabudak R, Dogulu CF, Nurlu G, Simsek H, Saatci I. Central nervous system demyelination in familial Mediterranean fever: is it a coincidence? Eur J Neurol 2003;10:327-8
  9. Wu B, Xu T, Li Y, Yin X. Interventions for reducing inflammation in familial Mediterranean fever. Cochrane Database Syst Rev 2015;3:CD010893
  10. Tunca M, Tankurt E, Akbaylar Akpinar H, Akar S, Hizli N, Gönen O. The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study. Br J Rheumatol 1997;36:1005-8
  11. Calguneri M, Apras S, Ozbalkan Z, Ozturk MA, Ertenli I, Kiraz S. The efficacy of continuous interferon alpha administration as an adjunctive agent to colchicineresistant familial Mediterranean fever patients. Clin Exp Rheumatol 2004;22:41-4
  12. Tweezer-Zaks N, Rabinovich E, Lidar M, Livneh A. Interferon-alpha as a treatment modality for colchicine- resistant familial Mediterranean fever. J Rheumatol 2008;35:1362-5
  13. Tunca M, Akar S, Soytürk M, Kirkali G, Resmi H, Akhunlar H, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebocontrolled trial. Clin Exp Rheumatol 2004;22:37-40
  14. Unal A, Emre U, Dursun A, Aydemir S. The co-incidence of multiple sclerosis in a patient with familial Mediterranean fever. Neurol India 2009;57:672-3
  15. Yücesan C, Canyi¤it A, Türkçapar N. The coexistence of familial Mediterranean fever with multiple sclerosis. Eur J Neurol 2004;11:716-7
  16. Canpolat M, Gumus H, G